Dr. Alexander Wyatt

Dr. Wyatt

B.Sc. (Biology), University of Nottingham
D.Phil. (Physiology, Anatomy and Genetics), University of Oxford

Team: 
Clinical and Research Scientists
Positions: 

Senior Research Scientist, Vancouver Prostate Centre
Scientist, Michael Smith Genome Sciences Centre, BC Cancer
Assistant Professor, Department of Urologic Sciences, University of British Columbia

 

Dr. Wyatt is an Assistant Professor in genitourinary cancer genomics. He obtained a DPhil (PhD) in from the University of Oxford in the UK and carried out his postdoctoral training at the Vancouver Prostate Centre in Canada. Dr. Wyatt has a background in basic human genetics, and 8 years of experience in cancer bioinformatics and the analysis of complex datasets. The primary research goals of his laboratory are to dissect the clinical relevance of genomic alterations in metastatic genitourinary cancers, and develop minimally-invasive biomarkers for guiding therapy selection. His team have established a variety of custom next-generation sequencing techniques and novel bioinformatics approaches to interrogate tissue and liquid biopsies from patients enrolled on a series of ongoing clinical trials and protocols.

The Wyatt lab works very closely with Dr. Kim Chi, Dr. Martin Gleave, and other senior medical oncologists and urologists at the Vancouver Prostate Centre and UBC, and together they have recently demonstrated that plasma circulating tumor DNA (ctDNA) is highly representative of metastatic lesions in prostate and bladder cancer, and that somatic alterations detected in ctDNA can help predict therapy resistance or response. The lab currently runs a phase II ‘umbrella trial’ to prospectively test this concept in 500 patients with metastatic prostate cancer. Dr. Wyatt’s team also leverages the serial sampling afforded by ctDNA to study how the prostate tumor genome evolves under the evolutionary pressures of different therapeutic regimens. They are particularly interested in changes to the AR gene, and how DNA repair defective prostate cancer responds to treatment.

Dr. Wyatt has been the recipient of multiple awards including a Coalition to Cure Prostate Cancer Young Investigator Award from the Prostate Cancer Foundation, a Movember Rising Star in Prostate Cancer Research Award from Prostate Cancer Canada and an Early Career Investigator Award from the Canadian Institutes of Health Research.

Learn more about Wyatt lab research at http://blogs.ubc.ca/wyattlab/ (opens in new window)

 

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Conference Flyer Page 1

Breast & Prostate Cancer half-day virtual conference: Saturday, September 18th, 2021

The What you Need to Know for Your Patients Post Breast & Prostate Cancer Conference, taking place online on Saturday, September 18th, 2021 from 8:00am – 1:30pm, is an accredited virtual half-day conference focusing on screening, treatment, side-effect management & emerging new therapies for breast & prostate cancer patients. Click here for more information and to register. 

Dr. Peter Black, team captain

Terry Fox Run fundraiser: September 19th, 2021

The 41st Annual Terry Fox Run is taking place on Sunday September 19, 2021. If you are able, please consider donating to our team (tax receipts issued), raising funds for the Terry Fox Foundation's ground-breaking cancer research. 

Employment

Work at the Vancouver Prostate Centre

Wednesday, September 8, 2021

Recent publication proposes a potential new therapeutic approach to treatment-resistant prostate cancer

Tuesday, August 3, 2021

Dr. Cherkasov receives 2021 Faculty of Medicine Distinguished Achievement Award

Dr. Cherkasov